Neck-and-Neck in Nephrology
Executive Summary
Nabi with PhosLo and Genzyme with Renagel now split the market for dialysis patients requiring treatment for high phosphate levels. Soon a third firm will enter the fray--the UK's Shire. Thus far, the marketing battle has been fought with nitty-gritty clinical data. But now Genzyme is raising the notion of "accumulation" to stigmatize competitors, while Nabi emphasizes the issue of cost. The competitive stakes are rising because Medicare changes in 2006 will dramatically expand the market.
You may also be interested in...
Ilypsa Inc.
Ilypsa is a spin-out of Symyx Technologies, a manufacturer of innovative materials for such industrial clients such as Dow Chemical and Agfa-Gevaert. The company had honed an ability to rapidly screen miniscule amounts of thousands of polymers for interesting functions. Symyx's founders quickly recognized that the company's platform was a potential therapeutic gold mine. Ilypsa was thus founded to focus on pharmaceutical applications.
Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Need a specific report? 1000+ reports available
Buy Reports